Home Approval of new antibiotic by Cubist to help in $100 trillion global fight
 

Keywords :   


Approval of new antibiotic by Cubist to help in $100 trillion global fight

2014-12-22 17:40:08| Biotech - Topix.net

Friday's FDA approval of the latest new antibiotic by Cubist Pharmaceuticals is a step toward combating a problem estimated to kill 10 million people and cost $100 trillion globally by 2050. Late Friday, U.S. regulators gave the nod to Zerbaxa, formerly known by the generic name of ceftolozane/tazobactam, for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections caused by certain so-called Gram-negative bacteria, typically considered among the hardest to kill.

Tags: global fight approval antibiotic

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Boeing makes 38% pay rise offer in bid to end strike
01.11The house paints that promise much more than colour
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11How Japan's youngest CEO transformed Hello Kitty
31.10Unicharm to Expand in Africa
More »